FASLODEXTM is indicated as monotherapy for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- Not previously treated with endocrine therapy, or
- With disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy
Faslodex is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
- In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone agonist.
FASLODEX MONOTHERAPY AFTER PRIOR ENDOCRINE THERAPY
CONFIRM STUDY PATIENT POPULATION
Patients had HER2 - locally advanced or metastatic ER+ and/or PgR + disease2
The median number of disease sites was 2, with levels of metastatic disease from bone-only to visceral involvement2
- 64% of patients had visceral involvement2
mBC=metastatic breast cancer.
|Time of relapse/progression
||FASLODEX 500 mg (n=362)
||FASLODEX 250 mg (n=374)
|During adjuvant therapy
Early relapse = 0-12 months after completion of adjuvant endocrine therapy
Late relapse = >12 months after completion of adjuvant endocrine therapy and after progression on first-line endocrine therapy for advanced disease
De novo = Patients presenting with de novo advanced disease and experiencing progression on first-line endocrine therapy
The majority of patients were responsive to their last hormonal therapy before randomisation2
65% responsive|| to last hormonal therapy before
35% not responsive¶ to last hormonal therapy before
The majority were under 65 years of age, with a median of 61 years2